AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 12 min read$RNXT

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.

Original reporting
globenewswire.com
Published Oct 1, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
8/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

The case series provides the first peer‑reviewed clinical evidence supporting the platform, which could influence valuation and partnership interest.

02

Market read

New clinical data may lift RNXT shares and affect the broader targeted oncology device market.

03

What to watch

Small sample size and lack of control group limit the robustness of the findings.

Relevance 8/10Novelty 8/10Timing: today

Background

RenovoRx (NASDAQ: RNXT) develops the Trans‑Arterial Micro‑Perfusion (TAMP) platform and the RenovoCath device for localized drug delivery.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx announced a peer‑reviewed case series showing tumor response and CA 19‑9 reductions using its FDA‑cleared RenovoCath TAMP platform in locally advanced pancreatic cancer.

Expected impact

likely upward pressure as investors price in the supportive data.

Evidence & confidence

First disclosure of clinical case results; data are favorable and may improve market perception of the device and pipeline.

Market effects

Sector

Strengthens the targeted drug‑delivery device sector and may boost comparable oncology device companies.

Regional

Potentially positive for US biotech and medical‑device investors.

Global

Adds to global interest in intra‑arterial chemotherapy approaches.

Counterpoint

What could challenge this read

Early case series may not translate to larger trials; investors should watch for Phase III results before committing.

Key entities

  • company
    RenovoRx, Inc.

    US‑listed biotech developing the TAMP platform.

  • institution
    Hackensack Meridian Health Jersey Shore University Medical Center

    Site where the case series was conducted.

Read at source← All news

Related articles

AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 25
$RNXTMedAI 8/10

RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site

RenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d

stocktitan.net3 min
AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min
AUG 13
$RNXTMedAI 8/10

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.

fool.com6 min
AUG 11
$RNXTMed

RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.

finanznachrichten.de2 min